GLAXOSMITHKLINE: GSK makes long-awaited move to split the group in two parts | NEUTRAL | 1660p vs. 1620p
GLAXOSMITHKLINE - NEUTRAL | 1660p vs. 1620p (+10%)GSK makes long-awaited move to split the group in two parts
The future exit of CHC is a good way to deleverage Pharma
A positive move but some concerns remain
An accretive deal to partially offset dilution from Tesaro
Back to our figures before Tesaro. Slight increase of our FV
GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.